Soluble guanylate cyclase: a potential therapeutic target for heart failure
Mihai Gheorghiade(Northwestern University), Javed Butler(University of Mississippi Medical Center), Stephen J. Greene(Duke University), Michael Böhm(Saarland University), John G.F. Cleland(Imperial College London), Piotr Ponikowski(Wroclaw Medical University), Marco Metra(GoHypersonic (United States)), Sean P. Collins(Mayo Clinic), Umberto Campia(Northwestern University), Gregg C. Fonarow, Adriaan A. Voors, Naoki Sato(British Heart Foundation), Hani N. Sabbah(Henry Ford Hospital), Phillip D. Levy(Wayne State University), John C. Burnett(Mayo Clinic), Johannes-Peter Stasch(Bayer (United States)), Lothar Roessig(Bayer (Germany)), Catherine N. Marti(Emory University), Bertram Pitt(University of Michigan–Ann Arbor)
Cited by 155
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k